Bausch Health Co. Inc. (BHC) – PRNewswire
-
OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease
-
SALIX PHARMACEUTICALS RELEASES LIVER HEALTH ANNUAL TRENDS REPORT UNDERSCORING CHALLENGES IN CARING FOR GROWING CHRONIC LIVER DISEASE AND CIRRHOTIC PATIENT POPULATION
-
Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022
-
SALIX PHARMACEUTICALS APPLAUDS IMPLEMENTATION OF K76.82 - A NEW ICD-10 CODE FOR HEPATIC ENCEPHALOPATHY
-
Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations
-
Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations
-
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin
-
Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations
-
Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes
-
Bausch Health Continuing Process Toward Separating Bausch + Lomb
-
Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit
-
Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)
-
BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS
-
Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation
-
Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9
-
Bausch + Lomb Provides Leadership Update
-
Salix Announces 2022 Gastrointestinal Health Scholars Program Winners
-
Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors
-
Bausch Health Issues Form 8-K for 2022 Annual Meeting of Shareholders Presentation
-
Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2022
-
Bausch Health Provides Update on Solta Medical
-
Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022
-
Bausch Health Announces Participation In Upcoming Investor Conferences
-
Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions
-
Bausch Health Companies Inc. Announces First-Quarter 2022 Results
-
Bausch Health Announces Thomas J. Appio As Chief Executive Officer
-
Bausch + Lomb Corporation Announces Pricing of IPO
-
Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting
-
Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10
-
Bausch + Lomb Corporation Announces Launch of IPO and Roadshow
-
Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation
-
Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting
-
Ortho Dermatologics Will Present Data at the 2022 Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference
-
Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting
-
Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
-
Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health
-
Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting
-
SALIX PHARMACEUTICALS WILL PRESENT SCIENTIFIC DATA AT THE SOCIETY OF HOSPITAL MEDICINE CONVERGE 2022
-
HALF OF IBS PATIENTS SURVEYED REPORT IBS SYMPTOMS MORE CHALLENGING TO MANAGE IN THE PAST YEAR
-
Bausch Health Will Reduce Debt By $200 Million
-
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associa
-
New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR® Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency De
-
Gary Gemignani Will Join Solta Medical Corporation As Chief Financial Officer
-
Ortho Dermatologics Will Present New Data at the 2022 American Academy of Dermatology Annual Meeting
-
Bausch Health Announces Participation in Upcoming Investor Conferences
-
Ortho Dermatologics Now Accepting Applications for 2022 Aspire Higher Scholarship Program
-
Salix and Colon Cancer Coalition Join Forces for 'Faces of Blue' Story Series to Raise Awareness of Colorectal Cancer Screenings
-
Bausch Health Announces Participation At The J.P. Morgan Global High Yield & Leveraged Finance Conference
-
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2021 Results And Provides 2022 Guidance
-
OraPharma Launches OraFit™ Custom Clear Dental Aligner System
Back to BHC Stock Lookup
